Antiplatelet agents (PAA) oral monotherapy is the cornerstone of treatment for prevention secondary atherothrombotic disease. Three million French take the low-dose aspirin (AFD) with a net clinical benefit of 10 events ischemic prevented (cardiovascular death, myocardial infarction or accident stroke) for a major bleeding (including 90% of gastrointestinal origin). close one million French take clopidogrel low dose (Plavix "75mg / d) with half in association with AFD (dual platelet inhibitors). the report risk-benefit of this combination therapy is 2 ischemic events prevented for a major bleeding event.